Minutes from the EMA-EUnetHTA December 2018 Meeting now available

The minutes from the EMA-EUnetHTA Meeting, hosted by the European Medicines Agency on 7th December 2018, are now available for access. This was the 16th meeting between the EMA and EUnetHTA, with representatives from both organisations in attendance as well as attendance from the European Commission. In addition, payer organisations attended as observers. Agenda topics […]

Open Call for Patient Input for a new Joint Assessment on a medicinal product for the prevention of vaso-occlusive crises in sickle cell disease (SCD) patients aged 16 years and over.

Patient group input requested for a new Joint Assessment on a medicinal product for the prevention of vaso-occlusive crises in sickle cell disease (SCD) patients aged 16 years and over. EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge […]

OTCA19 – ”Screening for osteoporosis in the general population” final assessment and related documentation is now available

EUnetHTA is pleased to announce that the final project plan, final assessment, comments from the external experts and authors’ answers, together with the final abstract and plain language summary for OTCA19 “Screening for osteoporosis in the general population” are now available for access. There were no manufacturers involved in this project. Screening for osteoporosis aims […]

The public consultation of the draft methodological guideline “Practical considerations when critically assessing economic evaluations” is OPEN (deadline Oct. 11, 2019)

We are pleased to announce that, as of today, the draft methodological guideline “Practical considerations when critically assessing economic evaluations”, produced within WP6 B2, has entered the public consultation phase. This consultation will be open until 11th October, 2019.   Objective of the methodological guideline EUnetHTA´s methodological guidelines are targeted to the needs of health […]

OTCA22 – “Clinical utility of Point-of-care Tests (POCT) D-Dimer and Troponin” project plan and comments from external experts are now available.

EUnetHTA is pleased to announce that the project plan and and comments from external experts for the Other Technologies Collaborative Assessment OTCA22 “Clinical utility of Point-of-care Tests (POCT) D-Dimer and Troponin” are now available for access. The final assessment report will be published on 29th November, 2019. Please access the project plan and external expert […]

Minutes from 2018 EUnetHTA-EFPIA Technical Meeting now available

The minutes from the EUnetHTA-EFPIA Technical Meeting, held on 11th December 2018 at the Haute Autorité de Santé in Paris, are now available for access. Participants included attendees from both EFPIA and EUnetHTA, as well as the EMA and DG SANTE. Topics presented and discussed included: Governance changes in EUnetHTA; Various developments and experiences from […]

The public consultation of the revision of the methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness” is OPEN (deadline 27th September, 2019)

We are pleased to announce that, as of today, a revised version of the methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness”, produced within WP6 B2, has entered the public consultation phase. This consultation will be open until 27th September, 2019. PLEASE NOTE: This was initially 13th […]

PTJA07 Pharmaceutical Joint Assessment Now Available – ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.

This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of the indication for ustekinumab to include treatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to or were intolerant to […]

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.